Genetically confirmed transthyretin amyloidosis primarily diagnosed as hypertrophic cardiomyopathy

Pol Arch Intern Med. 2022 Feb 28;132(2):16163. doi: 10.20452/pamw.16163. Epub 2021 Dec 3.

Authors

Michał Susuł¹, Paweł Petkow-Dimitrow^{2

3}, Renata Rajtar-Salwa²

Affiliations

¹ Department of Clinical Cardiology and Cardiovascular Interventions, Institute of Cardiology, University Hospital, Kraków, Poland. susul.michal@gmail.com
² Department of Clinical Cardiology and Cardiovascular Interventions, Institute of Cardiology, University Hospital, Kraków, Poland
³ Department of Cardiology, Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland

PMID: 34856785
DOI: 10.20452/pamw.16163

No abstract available

MeSH terms

Amyloid Neuropathies, Familial* / diagnosis
Amyloid Neuropathies, Familial* / genetics
Cardiomyopathy, Hypertrophic* / diagnosis
Cardiomyopathy, Hypertrophic* / genetics
Humans

Supplementary concepts

Amyloidosis, Hereditary, Transthyretin-Related